Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).

Hecht, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY.
J Clin Oncol. 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8.